Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-Targeting CAR-NK Cells in Recurrent/Refractory Ovarian Cancer
NCT07617753Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube carcinoma (PFTC) (3 arms), sponsored by Biotech Pharmaceutical. Primary endpoints: Dose-Limiting Toxicities at 28 days and Treatment-Emergent Adverse Events at 12 months. Started Mar 2026; status: recruiting.
02
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT07617753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617753.